IC
APLS

IEQ Capital’s Apellis Pharmaceuticals APLS Stock Holding History

IEQ Capital’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-25,500
Closed -$641K – 1894
2025
Q4 		$641K Sell
25,500
-271,284
-91% -$6.36M ﹤0.01% 1218
2025
Q3 		$6.72M Sell
296,784
-50,139
-14% -$1.17M 0.02% 417
2025
Q2 		$6.01M Buy
346,923
+55,065
+19% +$1.02M 0.04% 376
2025
Q1 		$6.38M Buy
291,858
+165,148
+130% +$4.56M 0.05% 285
2024
Q4 		$4.04M Buy
126,710
+118,404
+1,426% +$3.56M 0.04% 318
2024
Q3 		$240K Buy
+8,306
New +$308K ﹤0.01% 1002

Other funds holding APLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

IEQ Capital's APLS Position: Q1 2026 in Review

IEQ Capital sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 25,500 shares — an estimated $641K sold.

IEQ Capital first reported a position in APLS in Q3 2024 and held it in 6 quarters. The position peaked at $6.72M in Q3 2025. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • IEQ Capital reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • IEQ Capital sold 25,500 Apellis Pharmaceuticals shares in Q1 2026, an estimated $641K.
  • IEQ Capital first reported a position in Apellis Pharmaceuticals in Q3 2024 and held it in 6 quarters.
  • IEQ Capital's Apellis Pharmaceuticals position peaked at $6.72M in Q3 2025.
  • 323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on IEQ Capital's 13F filing for Q1 2026, filed 15 May 2026.